Rice Hall James & Associates LLC Makes New $4.85 Million Investment in Lantheus Holdings, Inc. $LNTH

Rice Hall James & Associates LLC acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, HoldingsChannel reports. The institutional investor acquired 43,735 shares of the medical equipment provider’s stock, valued at approximately $4,852,000.

A number of other large investors also recently made changes to their positions in the company. Versor Investments LP bought a new stake in Lantheus in the 4th quarter valued at $519,000. Reinhart Partners LLC. lifted its holdings in shares of Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after buying an additional 34,501 shares in the last quarter. M&T Bank Corp acquired a new stake in shares of Lantheus during the fourth quarter worth $539,000. Epoch Investment Partners Inc. boosted its position in shares of Lantheus by 59.4% in the first quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock valued at $49,284,000 after acquiring an additional 242,222 shares during the period. Finally, First Trust Advisors LP boosted its position in shares of Lantheus by 287.6% in the first quarter. First Trust Advisors LP now owns 60,258 shares of the medical equipment provider’s stock valued at $4,571,000 after acquiring an additional 44,713 shares during the period. Institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

LNTH has been the topic of several research reports. Citizens Jmp restated a “market outperform” rating and issued a $115.00 price target on shares of Lantheus in a research note on Monday, June 29th. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Leerink Partners set a $102.50 target price on shares of Lantheus in a research report on Monday, August 3rd. Brookline Capital Markets cut shares of Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Mizuho lowered their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Wednesday, July 29th. Four analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $108.11.

Lantheus Stock Performance

NASDAQ:LNTH opened at $100.91 on Tuesday. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 24.37 and a beta of -0.03. Lantheus Holdings, Inc. has a fifty-two week low of $49.67 and a fifty-two week high of $111.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The stock has a fifty day moving average price of $104.24 and a 200-day moving average price of $89.57.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.Lantheus’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the business earned $1.57 earnings per share. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.